VXRT News and Press, Vaxart Inc. From 09/17/20

Source: Altimmune Website Company Background: Altimmune ( ALT ) is a US biopharmaceutical company based in Gaithersburg, Maryland, USA, which focuses on developing treatments for liver disease, immune-modulating therapies, and vaccines. Altimmune has various pre-clinical to clinical ...

Inovio Pharmaceuticals ( INO +27.0% ) is up on over 80% higher volume. Shares have rallied  73%  since Monday's corporate overview virtually presented by CEO Joseph Kim at H.C. Wainwright's Global Investment Conference. COVID-related highlights : More news on: Inovio Pharmac...

Gainers: Novus Therapeutics (NASDAQ: NVUS ) +162% . More news on: Novus Therapeutics, Inc., Marinus Pharmaceuticals, Inc., Plus Therapeutics, Inc., Stocks on the move, , Read more ...

Tiny Vaxart   (NASDAQ: VXRT) was just a penny stock back in January. Few people had heard of the company. You could buy a share for only 34 cents. And then COVID-19 hit, followed by stay-at-home orders, economic shut-downs, and the current recession. The public health crisis sent the enti...

Companies across the healthcare spectrum are involved in the fight against COVID-19. Some are working on treatments for the disease, while others have rushed to create accurate test kits that can detect traces of the SARS-CoV-2 virus in mere minutes. It's the companies working on vaccines for th...

Gainers:  Immunomedics (NASDAQ: IMMU ) +100% . More news on: Immunomedics, Inc., Cassava Sciences, Inc., Vaxart, Inc., Stocks on the move, , Read more ...

Shares of Vaxart (NASDAQ: VXRT) were soaring 20.8% as of 11:22 a.m. EDT on Monday. The huge jump came after the biotech announced Food and Drug Administration clearance to begin a phase 1 clinical trial for Vaxart's oral coronavirus vaccine candidate. Vaxart reported promising pre-clinical...

Immunomedics (NASDAQ: IMMU )   +106%  after Gilead to buy the company for $21B (~$88/share). More news on: Immunomedics, Inc., Cassava Sciences, Inc., China Natural Resources, Inc., , Stocks on the move, Read more ...

Vaxart's (NASDAQ: VXRT ) jumps  16% premarket  after the FDA  completed review  of its Investigational New Drug (IND) application for Phase 1 clinical trial evaluating Company's oral COVID-19 vaccine candidate. VXRT also provided an update on its COVID-19 program. ...

Recruitment for Phase 1 clinical study expected to start this month Data from ongoing hamster challenge study expected in October SOUTH SAN FRANCISCO, Calif., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc., a clinical-stage biotechnology company developing oral vaccines that are a...